A Patient With Stage III Locally Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Infusion FOLFIRINOX: Impressive Tumoral Response and Death due to Legionella pneumophila Infection: A Unique Case Report
Open Access
- 31 March 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 877334
Abstract
Patients affected by pancreatic ductal adenocarcinoma (PDAC) have very poor prognosis, whereby at a follow-up of 5 years, the mortality rate is very similar to the incidence rate. Globally, around 10% of patients are amenable to radical surgery at the time of diagnosis, which represents the only chance of cure or long-term survival for these patients. Almost 40% of patients with PDAC show locally advanced pancreatic cancer (LAPC). LAPC is not a metastatic disease, although it is not amenable to radical surgery. For these patients, systemic induction chemotherapy with intravenous FOLFIRINOX (5-fluorouracil, folic acid, irinotecan, oxaliplatin) regimen is administered, with the aim of conversion to surgery, although the conversion rate remains low, at approximately 10% to 15%. Pancreatic arterial chemotherapy has been explored to overcome the intrinsic tumor pancreatic resistance to systemic chemotherapy, where an intra-arterial port-a-cath is placed by means of interventional oncology techniques under angiographic guidance in the operating theater. Here, we treated a patient with an intra-arterially modified FOLFIRINOX regimen. Three courses were administered, and the patient experienced no adverse events. At the end of the third course, the patient rapidly developed lung failure due to nosocomial Legionella pneumophila infection, despite the impressive pathological tumor response shown in the autopsy report. This is a first and unique report that demonstrates that pancreatic intra-arterial FOLFIRINOX can be safe and efficacious. We believe that this preliminary result will be confirmed in the next patients to be enrolled and that it provides a glimmer of hope for patients with this lethal disease.Keywords
This publication has 40 references indexed in Scilit:
- Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancerAnti-Cancer Drugs, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980Annals of Oncology, 2013
- Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2012
- Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitorsCritical Reviews in Oncology/Hematology, 2011
- Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP TrialTrials, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A Phase I Trial of Arterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Unresectable Advanced Pancreatic Cancer after Vascular Supply Distribution via Superselective EmbolizationJapanese Journal of Clinical Oncology, 2008
- Intra-arterial Infusion Chemotherapy With 5-Fluorouracil and Cisplatin in Advanced Pancreatic CancerAmerican Journal of Clinical Oncology, 2008
- Thymidine Phosphorylase Profiles in Nonmalignant and Malignant Pancreatic Tissue. Potential Therapeutic Role of Capecitabine on Tumoral and Endothelial Cells and Tumor-Infiltrating MacrophagesImmunopharmacology and Immunotoxicology, 2005